Abstract
The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Current Topics in Medicinal Chemistry
Title: Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity
Volume: 3 Issue: 7
Author(s): Chidambaram Ramachandran and Brian P. Kennedy
Affiliation:
Keywords: Protein Tyrosine Phosphatase, Diabetes and Obesity, autophosphorylation, tyrosine phosphatase, phenotype
Abstract: The identification of autophosphorylation of the insulin receptor as a pivotal component in the signal transduction induced by insulin, initiated the hunt to identify the tyrosine phosphatase(s) that were responsible for regulating dephosphorylation, and thus inactivation of the receptor. Compelling evidence for the existence of an insulin receptor specific PTP has come from the remarkable phenotype of the PTP1B deficient mouse. PTP1B deficient mice display an insulin sensitive phenotype and are able to maintain glucose homeostasis with about half the level of circulating insulin. In response to insulin administration PTP1B deficient mice have a significant increase in insulin receptor phosphorylation in liver and muscle compared to wild type controls. Unexpectedly these animals were also resistant to diet induced obesity. These observations strongly support PTP1B as a negative regulator of insulin action, thereby making it an ideal therapeutic target for intervention in type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
Ramachandran Chidambaram and Kennedy P. Brian, Protein Tyrosine Phosphatase 1B: A Novel Target for Type 2 Diabetes and Obesity, Current Topics in Medicinal Chemistry 2003; 3 (7) . https://dx.doi.org/10.2174/1568026033452276
DOI https://dx.doi.org/10.2174/1568026033452276 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutraceuticals and Diet-based Phytochemicals in Type 2 Diabetes Mellitus: From Whole Food to Components with Defined Roles and Mechanisms
Current Diabetes Reviews Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency
Current Drug Safety Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets subject Index To Volume 1
Current Molecular Medicine Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative Stress in Allergic and Inflammatory Skin Diseases
Current Drug Targets - Inflammation & Allergy Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia
Reviews on Recent Clinical Trials Recent Development and Future Perspective of Antitubercular Therapy
Anti-Infective Agents in Medicinal Chemistry Change in INSR, APBA2 and IDE Gene Expressions in Brains of Alzheimer's Disease Patients
Current Alzheimer Research Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade
Endocrine, Metabolic & Immune Disorders - Drug Targets Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Current Pharmaceutical Design Further Perspectives on Diabetes: NeuroRegulation of Blood Glucose
Neuroscience and Biomedical Engineering (Discontinued) Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology